TRIESENCE®
|
|
|
THE TRIESENCE® Difference
|
|
|
|
|
*Coverage applies to Medicare Fee-for-Service only, based on quarterly CMS ASP Pricing File. Medicare Advantage and Commercial plan coverage may vary. Subject to program terms and limitations. Please contact 1-866-HROWINC (476-9462) for additional details.
**Coverage details are based on Benefit Verification (BV) results obtained through the Harrow Cares program; actual patient coverage may differ.
***TRIESENCE is indicated for ocular inflammatory conditions unresponsive to topical corticosteroids.
Important Safety Information:
TRIESENCE® is contraindicated in patients with systemic fungal infections or hypersensitivity to corticosteroids. Key risks include intraocular pressure elevation, infection, and cataract progression.
See full Prescribing Information at www.triesencehcp.com/TRI-00002_Triesence_Pl_web.pdf
References: 1. TRIESENCE Prescribing information. Harrow IP, LLC; 2024.
|
Novartis AG owns the TRIESENCE registered trademark and the TRIESENCE logo trademark. Harrow
and the Harrow logo are trademarks of Harrow IP, LLC. © 2025 Harrow. All Rights Reserved.
|
|
|
|
|
|
|
|
|
|
This content is sponsored by Harrow IP, LLC, and Specialty Practice Network has not independently reviewed or verified the information provided by Harrow IP, LLC. | | |